Vanguard's drop below the 5% threshold removes a passive holder from the 5%+ reporting requirement, but the reduction is small (likely less than 0.03% of shares outstanding). Monitor for any further 13G amendments or a 13D conversion if another large holder increases its position. The filing is routine for an index fund manager rebalancing.
Price Chart
Executive Summary
Vanguard Capital Management filed an amended Schedule 13G disclosing a 4.97% passive stake in Collegium Pharmaceutical as of September 30, 2026, down from a prior 5%+ position. The filing indicates Vanguard reduced its holdings below the 5% threshold, signaling a partial exit by a major index fund manager.
Key Financial Metrics
Key Facts
- Vanguard Capital Management filed an amended Schedule 13G on October 30, 2026
- Beneficial ownership as of September 30, 2026: 1,621,026 shares (4.97% of common stock)
- Prior filing (not provided) showed Vanguard above the 5% threshold; this amendment drops below 5%
- Vanguard certifies passive intent under Rule 13d-1(b) and Rule 13d-1(c)
Financial Impact
Vanguard reduced its stake from above 5% to 4.97%, representing a decrease of approximately 1,621,026 shares held as of September 30, 2026. At the $756M market cap, the stake value is approximately $37.6M.
Risk Factors
- Passive stake reduction below 5% could signal reduced institutional interest, though Vanguard's move is likely index-driven
- No activist intent indicated; filing is purely passive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0002100119-26-001562 |
| Document: 0002100119-26-001562-index.html | 0002100119-26-001562 |
| Document: 0002100119-26-001562.txt | 0002100119-26-001562 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | SC 13G/A | $24.23 | awaiting T+1 | awaiting T+1 | $23.80 (−1.77%) |
Oct 29, 2026 3d ago | SC 13G/A | $24.03 $23.80 | ▼ −0.96% | ▲ +0.82% | $23.80 (−0.96%) |
Oct 29, 2026 3d ago | Press Release | $24.03 $23.80 | ▼ −0.96% | ▲ +0.82% | $23.80 (−0.96%) |
Oct 22, 2026 10d ago | Press Release | $23.50 $22.96 | ▼ −2.30% | ▼ −1.78% | $23.80 (+1.28%) |
Oct 19, 2026 13d ago | 8-K | $23.23 $22.92 | ▼ −1.36% | ▼ −1.88% | $23.80 (+2.45%) |
Oct 8, 2026 24d ago | SC 13G/A | $22.09 $22.05 | ▼ −0.18% | ▼ −0.12% | $23.80 (+7.74%) |
Aug 19, 2026 10w ago | Court Ruling | $27.54 $27.11 | ▼ −1.56% | ▼ −1.97% | $23.80 (−13.58%) |
Aug 13, 2026 11w ago | 8-K | $28.15 $28.23 | ▲ +0.28% | ▲ +0.48% | $23.80 (−15.45%) |
Aug 6, 2026 12w ago | 8-K | $29.11 $29.47 | ▲ +1.24% | ▲ +0.63% | $23.80 (−18.24%) |
May 15, 2026 24w ago | Insider Cluster | $33.65 $33.62 | ▼ −0.09% | ▲ +0.56% | $23.80 (−29.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers